Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Fluorouracil, Oxaliplatin, Panitumumab in patients with Colorectal Adenocarcinoma.
The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.
This statement is based on a regulatory approval from the European Medicines Agency:
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.